Just a week after the approval for the HIV therapy Tivicay under GlaxoSmithKline PLC’s joint venture with Pfizer Inc. – ViiV Healthcare – GSK’s plans for a surge in new drug launches hit a snag with the Phase III failure of the pharma giant’s oral Crohn’s disease therapy vercirnon, licensed from ChemoCentryx Inc.
Vercirnon, a specific CCR9 chemokine receptor inhibitor, was on a list of assets that GSK has pointed to as early...